These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0.23, 0.6 and 1.5 T MRI, a part of a phase I trial. Chabanova E; Thomsen HS; Løgager V; Moller JM; Brage K; Fogh K; Bovin J; Elmig J MAGMA; 2004 Sep; 17(1):28-35. PubMed ID: 15258827 [TBL] [Abstract][Full Text] [Related]
4. Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement. Rief M; Huppertz A; Asbach P; Franiel T; Schwenke C; Hamm B; Taupitz M; Wagner M Invest Radiol; 2010 Sep; 45(9):565-71. PubMed ID: 20644484 [TBL] [Abstract][Full Text] [Related]
5. A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects. Jørgensen JT; Rief M; Brismar TB; Wagner M; Albiin N Acta Radiol; 2012 Sep; 53(7):707-13. PubMed ID: 22821959 [TBL] [Abstract][Full Text] [Related]
7. Orally administered manganese with and without ascorbic acid as a liver-specific contrast agent and bowel marker for magnetic resonance imaging: phase I clinical trial assessing efficacy and safety. Leander P; Golman K; Månsson S; Höglund P Invest Radiol; 2010 Sep; 45(9):559-64. PubMed ID: 20644487 [TBL] [Abstract][Full Text] [Related]
9. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Wang C Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956 [TBL] [Abstract][Full Text] [Related]
15. [Manganese-DPDP in the MR tomography of malignant liver tumors. The initial results with a new hepatobiliary contrast agent]. Steudel A; Layer G; Kraheck H; Hartlapp J; Reiser M Rofo; 1992 May; 156(5):460-4. PubMed ID: 1596550 [TBL] [Abstract][Full Text] [Related]
16. Increased manganese concentration in the liver after oral intake. Thomsen HS; Svendsen O; Klastrup S Acad Radiol; 2004 Jan; 11(1):38-44. PubMed ID: 14746400 [TBL] [Abstract][Full Text] [Related]
17. Visualization of bile movement using MRI spin-labeling technique: preliminary results. Gonoi W; Akahane M; Watanabe Y; Isono S; Maeda E; Hagiwara K; Ohtomo K AJR Am J Roentgenol; 2013 Jul; 201(1):133-41. PubMed ID: 23789667 [TBL] [Abstract][Full Text] [Related]
18. [Optimization of dosage and exam technique in the use of oral contrast media in magnetic resonance]. Broglia L; Tortora A; Maccioni F; Arpesani R; Marcelli G; Ascarelli A; Rossi P Radiol Med; 1999 May; 97(5):365-70. PubMed ID: 10432968 [TBL] [Abstract][Full Text] [Related]
19. Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T--Initial Experience. Krautmacher C; Willinek WA; Tschampa HJ; Born M; Träber F; Gieseke J; Textor HJ; Schild HH; Kuhl CK Radiology; 2005 Dec; 237(3):1014-9. PubMed ID: 16237142 [TBL] [Abstract][Full Text] [Related]
20. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats. Kreft BP; Baba Y; Tanimoto A; Finn JP; Stark DD Radiology; 1993 Feb; 186(2):543-8. PubMed ID: 8421762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]